Nuclea Biotech Mass Spec-Based Assays
Nuclea Biotechnologies said it will start offering more than 50 research-use-only mass spectrometry-based biomarker tests as part of its laboratory services. The tests are designed to detect and quantify key protein biomarkers in human serum or plasma and are available to pharmaceutical firms for clinical trials, to researchers, and as companion diagnostics. Nuclea recently established its first CLIA/CAP certified clinical service laboratory in Pittsfield, Massachusetts, where it offers an array of fully validated and reimbursable IHC and ELISA tests for cancer-associated proteins in tissue and blood. Nuclea will launch a second, high-complexity CLIA lab in its Cambridge, Massachusetts facility in late 2015. In addition to IHC and ELISA tests, this lab will offer mass spec-based multiplexed assays for serum or plasma proteins associated with diabetes, metabolic syndrome, and obesity.